Bristol Myers Squibb launches initiative to ensure disability diversity in clinical trials
Bristol Myers Squibb (BMS) has launched the Disability Diversity in Clinical Trials (DDiCT) initiative to ensure equal access to clinical trials, ensuring all patient groups are ‘reflective of the real-world population’.
Launched in collaboration with Disability Solutions, a US-based non-profit organisation supporting companies globally to achieve disability inclusion, the DDiCT initiative will aim to make recommendations on how to ‘effectively improve access, engagement, speed of enrolment and participation of people with disabilities in clinical trials’.
The initiative, which aligns with BMS’ broader inclusion and diversity health equity commitments, was initiated by the company’s People & Business Resource Group Disability Advancement Workplace Network (DAWN) and will be co-led by DAWN and the Global Drug Development Team.
Commenting on the launch, Tinamarie Duff, DAWN global people and business resource group lead, BMS, said: “People with disabilities are omitted from conversations about diversity and inclusion, despite being the largest underrepresented group in the world and the only underrepresented group anyone can join at any given moment. Therefore, it’s essential that we broaden the scope of medical trials and research.
Read more: https://www.pmlive.com/pharma_news/bristol_myers_squibb_launches_initiative_to_ensure_disability_diversity_in_clinical_trials_1452484
Launched in collaboration with Disability Solutions, a US-based non-profit organisation supporting companies globally to achieve disability inclusion, the DDiCT initiative will aim to make recommendations on how to ‘effectively improve access, engagement, speed of enrolment and participation of people with disabilities in clinical trials’.
The initiative, which aligns with BMS’ broader inclusion and diversity health equity commitments, was initiated by the company’s People & Business Resource Group Disability Advancement Workplace Network (DAWN) and will be co-led by DAWN and the Global Drug Development Team.
Commenting on the launch, Tinamarie Duff, DAWN global people and business resource group lead, BMS, said: “People with disabilities are omitted from conversations about diversity and inclusion, despite being the largest underrepresented group in the world and the only underrepresented group anyone can join at any given moment. Therefore, it’s essential that we broaden the scope of medical trials and research.
Read more: https://www.pmlive.com/pharma_news/bristol_myers_squibb_launches_initiative_to_ensure_disability_diversity_in_clinical_trials_1452484
